Exelixis
EXEL
#1790
Rank
NZ$20.07 B
Marketcap
NZ$74.87
Share price
-3.45%
Change (1 day)
21.61%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): NZ$4.95

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$4.89. In 2023 the company made an earnings per share (EPS) of NZ$1.10 an increase over its 2022 EPS that were of NZ$0.96.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$4.95
2023NZ$1.1014.61%
2022NZ$0.96-22.97%
2021NZ$1.25100%
2020NZ$0.63-65.09%
2019NZ$1.79-53.91%
2018NZ$3.89333.96%
2017NZ$0.90-260.61%
2016NZ-$0.56-58.75%
2015NZ-$1.35-42.45%
2014NZ-$2.355.3%
2013NZ-$2.23

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
NZ$18.83 285.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$2.30-52.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$24.23 395.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$3.49-28.54%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$12.36 152.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$5.85 19.72%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$6.37 30.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
NZ-$6.21-226.99%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.42-129.07%๐Ÿ‡บ๐Ÿ‡ธ USA